Insights on the Irritable Bowel Syndrome with Diarrhea Global Market to 2028 - by Drugs, Prescription Type and Geography - ResearchAndMarkets.com

The "Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028" report has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Thursday, February 18, 2021
Information
Tags: 
General Health, Pharmaceutical, Health, Digestive diseases, Clinical medicine, Medical specialties, Abdominal pain, Waterborne diseases, Feces, Irritable bowel syndrome, Diarrhea, Small intestinal bacterial overgrowth, Alosetron
Geotags: 
US
⚠generated by AI ↴
Summary
Key Points: 
  • The "Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global irritable bowel syndrome with diarrhea market is rising at a significant pace, projected to rise at a CAGR of 11.3% during the estimated period from 2020 to 2028, starting from US$ 423.3 Mn in 2019.
  • Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market.
  • In addition, increasing demand for spicy food drastically alters the bowel peristaltic activity causing fluid stool, thereby the irritable bowel syndrome with Diarrhea market is expected to witness significant growth during the forecast period from 2020 to 2028.


The "Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2020 to 2028" report has been added to ResearchAndMarkets.com's offering.

The global irritable bowel syndrome with diarrhea market is rising at a significant pace, projected to rise at a CAGR of 11.3% during the estimated period from 2020 to 2028, starting from US$ 423.3 Mn in 2019.

Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as a breakthrough step in the long struggle to discover an effective treatment for IBS-D.

Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off-label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due to the introduction of the said novel drugs.

In addition, lockdown restrictions and the need to maintain social distancing due to the ongoing COVID-19 pandemic have resulted in more number of people staying at home. Hence, a sedentary lifestyle has resulted in the development of irritable bowel syndrome. In addition, increasing demand for spicy food drastically alters the bowel peristaltic activity causing fluid stool, thereby the irritable bowel syndrome with Diarrhea market is expected to witness significant growth during the forecast period from 2020 to 2028.

Companies Mentioned

  • Astellas Pharmaceuticals
  • Actavis
  • Pfizer
  • GlaxoSmithKline
  • Salix Pharmaceuticals Ltd
  • AstraZenenca

Key questions answered in this report:

  • What are the current market trends and dynamics in the irritable bowel syndrome with diarrhea market and valuable opportunities for emerging players?
  • Which segment accounts for the fastest CAGR during the forecast period?
  • What are the drivers of the irritable bowel syndrome with diarrhea market?
  • Notable developments going on in the irritable bowel syndrome with diarrhea market.
  • What is the market trend and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • A comparative scenario for all the segments for the years 2019 (actual) and 2028 (forecast)

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

2.1 Global IBS-D Drugs Market Portraiture

2.2 IBS-D Drugs Market, by Drug Type, 2019 Vs. 20

2.3 IBS-D Drugs Market, by Prescription Type, 2019 (USD Mn)

2.4 IBS-D Drugs Market Share, by Geography, 2019 (Value %)

Chapter 3 IBS-D Drugs Market: Market Dynamics and Outlook

3.1 Introduction, Facts and Figures

3.1.1 Potential Patient Population

3.1.2 Prevalent Treatment Options for IBS-D

3.2 Market Dynamics

3.2.1 Drivers

3.2.1.1 Perpetual growth in IBS prevalence

3.2.2 Challenges

3.2.2.1 Low diagnosis rate and insufficient effect of drugs

3.2.3 Opportunities

3.2.3.1 Strong product pipeline

3.3 Attractive Investment Proposition

3.4 Competitive Analysis

3.4.1 Fractal Map Investigation

Chapter 4 Global IBS-D Drugs Market Analysis, by Drugs

4.1 Preface

4.2 Eluxadoline

4.3 Alosetron

4.4 Rifaximin

4.5 Loperamide

4.6 Diphenoxylate + Atropine

4.7 Dicyclomine and Hyoscyamine

4.8 Pipeline Drug Analysis

Chapter 5 Global IBS-D Drugs Market Analysis, By Prescription Type

5.1 Prescribed and OTC Drugs

5.2 Prescribed Branded and Prescribed Generic Drugs

Chapter 6 Global IBS-D Drugs Market Analysis, By Geography

6.1 Preface

6.2 North America

6.2.1 United States

6.2.2 Canada

6.3 Europe

6.3.1 U.K.

6.3.2 Germany

6.3.3 Rest of Europe

6.4 Asia Pacific

6.4.1 China

6.4.2 Japan

6.4.3 Rest of Asia Pacific

6.5 Rest of the World (RoW)

Chapter 7 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/1v7472

Copyright: 
Copyright Business Wire 2021